ERBB2 and breast carcinoma: Around 15–20 % of breast cancers exhibit amplification and/or overexpression of HER2 (“HER2-positivity”) [4–6], which is associated with increased tumor aggressiveness, higher rates of recurrence, and increased mortality [6–11].